180 Wealth Advisors’s Gilead Sciences GILD Stock Holding History

180 Wealth Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1M	Sell	7,935 -1,236	-13%	-$163K	0.1%	201
2026 Q1	$1.28M	Buy	9,171 +151	+2%	+$21.1K	0.15%	153
2025 Q4	$1.11M	Sell	9,020 -813	-8%	-$98.8K	0.13%	166
2025 Q3	$1.09M	Sell	9,833 -2,554	-21%	-$290K	0.13%	155
2025 Q2	$1.37M	Buy	12,387 +1,427	+13%	+$152K	0.19%	118
2025 Q1	$1.23M	Sell	10,960 -30	-0.3%	-$3.1K	0.2%	115
2024 Q4	$1.02M	Buy	10,990 +4,920	+81%	+$443K	0.16%	127
2024 Q3	$509K	Sell	6,070 -101	-2%	-$7.71K	0.08%	222
2024 Q2	$432K	Buy	+6,171	New	+$412K	0.07%	247

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

180 Wealth Advisors's GILD Position: Q2 2026 in Review

180 Wealth Advisors reduced its Gilead Sciences (GILD) stake by 13% in Q2 2026, selling an estimated $163K and leaving 7,935 shares worth $1M. The position accounts for 0.1% of the portfolio, ranked #201.

180 Wealth Advisors first reported a position in GILD in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.37M in Q2 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

180 Wealth Advisors held 7,935 shares of Gilead Sciences worth $1M as of Q2 2026.
180 Wealth Advisors sold 1,236 Gilead Sciences shares in Q2 2026, an estimated $163K.
Gilead Sciences made up 0.1% of 180 Wealth Advisors's portfolio in Q2 2026, its #201 holding.
180 Wealth Advisors first reported a position in Gilead Sciences in Q2 2024 and has held it in 9 quarters since.
180 Wealth Advisors's Gilead Sciences position peaked at $1.37M in Q2 2025.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.